Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) announced it has secured new intellectual property protection with the Canadian Patent Office granting a patent for PromarkerEso, the proprietary first-in-class blood test for esophageal adenocarcinoma.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) announced the appointment of David Morris as Chief Executive Officer (CEO) and Managing Director (MD).
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) announced that its US Reference Laboratory has received accreditation by the College of American Pathologists (CAP) based on results of a recent on-site inspection as part of the CAP's Accreditation Programs.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) announced it has secured new intellectual property protection with the US Patent Office granting a patent for PromarkerEso, the proprietary first-in-class blood test for esophageal adenocarcinoma (EAC).
Proteomics International Laboratories Ltd (ASX:PIQ) PromarkerD changes how Doctors manage DKD - study published
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, announced new clinical findings showing that its PromarkerD predictive blood test demonstrates promising prognostic accuracy for diabetic kidney disease (DKD) in Aboriginal people, one of the highest-risk populations for kidney failure globally.
TempraMed Technologies Ltd. (CNSX:VIVI) (FRA:9DY) announced that it has entered into a definitive exclusive distribution agreement with Dolfin Saglik Urunleri ("Dolfin Saglik") to market and sell TempraMed's "VIVI" line of medication temperature-stabilizing products throughout Turkey.
